Literature DB >> 18671886

Critical molecular abnormalities in high-grade serous carcinoma of the ovary.

Martin Köbel1, David Huntsman, C Blake Gilks.   

Abstract

Ovarian carcinomas show more morphological heterogeneity than adenocarcinomas of any other body site. It has recently become clear that the morphologically defined subtypes of ovarian carcinoma are distinct diseases, with different risk factors, molecular events during oncogenesis, likelihood of spread, responses to chemotherapy, and outcomes. This review focuses on molecular abnormalities (in genes expressing BRCA1/2, TP53 and RB1/CCND1/CDKN2A/E2F) found in high-grade serous carcinomas of the ovary, which account for most ovarian cancer deaths. These highly aggressive but chemosensitive tumours are associated with perturbation of molecular pathways leading to genomic instability and extreme mutability and present unique challenges in oncological research and practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18671886     DOI: 10.1017/S146239940800077X

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  22 in total

1.  The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube.

Authors:  Wa Xian; Alexander Miron; Michael Roh; Dana R Semmel; Yosuf Yassin; Judy Garber; Esther Oliva; Annekathryn Goodman; Karishma Mehra; Ross S Berkowitz; Christopher P Crum; Bradley J Quade
Journal:  J Pathol       Date:  2010-01       Impact factor: 7.996

2.  Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.

Authors:  Dimitra Dafou; Barbara Grun; John Sinclair; Kate Lawrenson; Elizabeth C Benjamin; Estrid Hogdall; Susanne Kruger-Kjaer; Lise Christensen; Heidi M Sowter; Ahmed Al-Attar; Richard Edmondson; Stephen Darby; Andrew Berchuck; Peter W Laird; C Leigh Pearce; Susan J Ramus; Ian J Jacobs; Simon A Gayther
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

3.  Molecular characterization of 103 ovarian serous and mucinous tumors.

Authors:  Ildikó Vereczkey; Orsolya Serester; Judit Dobos; Mónika Gallai; Orsolya Szakács; Zoltán Szentirmay; Erika Tóth
Journal:  Pathol Oncol Res       Date:  2010-12-07       Impact factor: 3.201

4.  Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.

Authors:  Mark S Carey; Roshan Agarwal; Blake Gilks; Kenneth Swenerton; Steve Kalloger; Jennifer Santos; Zhenlin Ju; Yiling Lu; Fan Zhang; Kevin R Coombes; Dianne Miller; David Huntsman; Gordon B Mills; Bryan T Hennessy
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531

5.  Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma.

Authors:  Chun Feng Lee; Zhi Qiang Ling; Ting Zhao; Shih Hua Fang; Weng Cheng Chang; San Chih Lee; Kuan Rong Lee
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

Review 6.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

7.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.

Authors:  Hui Zhang; Tao Liu; Zhen Zhang; Samuel H Payne; Bai Zhang; Jason E McDermott; Jian-Ying Zhou; Vladislav A Petyuk; Li Chen; Debjit Ray; Shisheng Sun; Feng Yang; Lijun Chen; Jing Wang; Punit Shah; Seong Won Cha; Paul Aiyetan; Sunghee Woo; Yuan Tian; Marina A Gritsenko; Therese R Clauss; Caitlin Choi; Matthew E Monroe; Stefani Thomas; Song Nie; Chaochao Wu; Ronald J Moore; Kun-Hsing Yu; David L Tabb; David Fenyö; Vineet Bafna; Yue Wang; Henry Rodriguez; Emily S Boja; Tara Hiltke; Robert C Rivers; Lori Sokoll; Heng Zhu; Ie-Ming Shih; Leslie Cope; Akhilesh Pandey; Bing Zhang; Michael P Snyder; Douglas A Levine; Richard D Smith; Daniel W Chan; Karin D Rodland
Journal:  Cell       Date:  2016-06-29       Impact factor: 41.582

8.  MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.

Authors:  Cheng-Han Lee; Subbaya Subramanian; Andrew H Beck; Inigo Espinosa; Janine Senz; Shirley X Zhu; David Huntsman; Matt van de Rijn; C Blake Gilks
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

9.  Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.

Authors:  C Blake Gilks
Journal:  J Oncol       Date:  2009-12-30       Impact factor: 4.375

10.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

Authors:  Jessica N McAlpine; Kimberly C Wiegand; Russell Vang; Bridgett M Ronnett; Anna Adamiak; Martin Köbel; Steve E Kalloger; Kenneth D Swenerton; David G Huntsman; C Blake Gilks; Dianne M Miller
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.